168 related articles for article (PubMed ID: 38685841)
1. The Confounding Role of Graft-Versus-Host Disease in Animal Models of Cancer Immunotherapy: A Systematic Review.
Ashraf H; Heydarnejad M; Kosari F
Arch Iran Med; 2024 Mar; 27(3):159-167. PubMed ID: 38685841
[TBL] [Abstract][Full Text] [Related]
2. Antileukemia and antitumor effects of the graft-versus-host disease: a new immunovirological approach.
Sinkovics JG
Acta Microbiol Immunol Hung; 2010 Dec; 57(4):253-347. PubMed ID: 21183421
[TBL] [Abstract][Full Text] [Related]
3. Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition.
Fisher SA; Cutler A; Doree C; Brunskill SJ; Stanworth SJ; Navarrete C; Girdlestone J
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009768. PubMed ID: 30697701
[TBL] [Abstract][Full Text] [Related]
4. Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease.
Chang YJ; Zhao XY; Huang XJ
Front Immunol; 2018; 9():3041. PubMed ID: 30619371
[TBL] [Abstract][Full Text] [Related]
5. Have we improved in preventing and treating acute graft-versus-host disease?
Perez L; Anasetti C; Pidala J
Curr Opin Hematol; 2011 Nov; 18(6):408-13. PubMed ID: 21912253
[TBL] [Abstract][Full Text] [Related]
6. Update of humanized animal disease models in studying Graft-versus-host disease.
Huang F; Cao FL; Zheng SG
Hum Vaccin Immunother; 2018; 14(11):2618-2623. PubMed ID: 30130452
[TBL] [Abstract][Full Text] [Related]
7. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Talmadge JE
Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
[TBL] [Abstract][Full Text] [Related]
8. The Role of Co-stimulatory/Co-inhibitory Signals in Graft-vs.-Host Disease.
Kumar S; Leigh ND; Cao X
Front Immunol; 2018; 9():3003. PubMed ID: 30627129
[TBL] [Abstract][Full Text] [Related]
9. Combination of anti-CD4 antibody treatment and donor lymphocyte infusion ameliorates graft-versus-host disease while preserving graft-versus-tumor effects in murine allogeneic hematopoietic stem cell transplantation.
Ueha S; Yokochi S; Ishiwata Y; Kosugi-Kanaya M; Shono Y; Shibayama S; Ito S; Matsushima K
Cancer Sci; 2017 Oct; 108(10):1967-1973. PubMed ID: 28787768
[TBL] [Abstract][Full Text] [Related]
10. Translational Clinical Strategies for the Prevention of Gastrointestinal Tract Graft
Rayasam A; Drobyski WR
Front Immunol; 2021; 12():779076. PubMed ID: 34899738
[TBL] [Abstract][Full Text] [Related]
11. T Cell Subsets in Graft Versus Host Disease and Graft Versus Tumor.
Jiang H; Fu D; Bidgoli A; Paczesny S
Front Immunol; 2021; 12():761448. PubMed ID: 34675938
[TBL] [Abstract][Full Text] [Related]
12. Advance in Targeted Immunotherapy for Graft-Versus-Host Disease.
Zhang L; Yu J; Wei W
Front Immunol; 2018; 9():1087. PubMed ID: 29868032
[TBL] [Abstract][Full Text] [Related]
13. Novel Humanized Peripheral Blood Mononuclear Cell Mouse Model with Delayed Onset of Graft-versus-Host Disease for Preclinical HIV Research.
Holguin L; Echavarria L; Burnett JC
J Virol; 2022 Feb; 96(3):e0139421. PubMed ID: 34818071
[TBL] [Abstract][Full Text] [Related]
14. International Society for Cell & Gene Therapy Stem Cell Engineering Committee: Cellular therapies for the treatment of graft-versus-host-disease after hematopoietic stem cell transplant.
Garcia-Rosa M; Abraham A; Bertaina A; Bhoopalan SV; Bonfim C; Cohen S; DeZern A; Louis C; Oved J; Pavel-Dinu M; Purtill D; Ruggeri A; Russell A; Sharma A; Wynn R; Boelens JJ; Prockop S
Cytotherapy; 2023 Jun; 25(6):578-589. PubMed ID: 36941149
[TBL] [Abstract][Full Text] [Related]
15. Intestinal helminths regulate lethal acute graft-versus-host disease and preserve the graft-versus-tumor effect in mice.
Li Y; Chen HL; Bannick N; Henry M; Holm AN; Metwali A; Urban JF; Rothman PB; Weiner GJ; Blazar BR; Elliott DE; Ince MN
J Immunol; 2015 Feb; 194(3):1011-20. PubMed ID: 25527786
[TBL] [Abstract][Full Text] [Related]
16. Acute graft-vs-host disease: pathobiology and management.
Goker H; Haznedaroglu IC; Chao NJ
Exp Hematol; 2001 Mar; 29(3):259-77. PubMed ID: 11274753
[TBL] [Abstract][Full Text] [Related]
17. Autologous graft-versus-host disease: a novel approach for antitumor immunotherapy.
Hess AD; Jones RJ; Morris LE; Noga SJ; Vogelsang GB; Santos GW
Hum Immunol; 1992 Jul; 34(3):219-24. PubMed ID: 1429045
[TBL] [Abstract][Full Text] [Related]
18. Low-intensity allogeneic hematopoietic stem cell transplantation for myeloid malignancies: separating graft-versus-leukemia effects from graft-versus-host disease.
Burroughs L; Storb R
Curr Opin Hematol; 2005 Jan; 12(1):45-54. PubMed ID: 15604891
[TBL] [Abstract][Full Text] [Related]
19. Regulatory T Cells in GVHD Therapy.
Guo WW; Su XH; Wang MY; Han MZ; Feng XM; Jiang EL
Front Immunol; 2021; 12():697854. PubMed ID: 34220860
[TBL] [Abstract][Full Text] [Related]
20. Insights into mechanisms of graft-versus-host disease through humanised mouse models.
Elhage A; Sligar C; Cuthbertson P; Watson D; Sluyter R
Biosci Rep; 2022 Sep; 42(9):. PubMed ID: 35993192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
